Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29172647 | 0.90 | CA1 (0.48) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL29087906 | 0.89 | LTA4H (0.45) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL4488619 | 0.89 | LTA4H (0.45) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL22455862 | 0.87 | LTA4H (0.44) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL4100347 | 0.84 | CA1 (0.44) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL6698682 | 0.84 | CA1 (0.42) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL996384 | 0.84 | CA1 (0.46) | CA1CYP2C19TSHRCA2CA7 | |
| SCHEMBL2182396 | 0.83 | CA1 (0.47) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL2223254 | 0.83 | CA1 (0.47) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL2076706 | 0.82 | CA1 (0.43) | CA1SLC1A3SLC1A2SLC1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1219953-A | Fabric softening compound/composition | PROCTER & GAMBLE (US) | 1999-06-16 | — | — | CN | claimed |
| CN-1196081-A | Concentrated, water dispersible, stable, fabric softening compositions | PROCTER & GAMBLE (US) | 1998-10-14 | — | — | CN | claimed |
| CN-1195369-A | Concentrated and stable fabric softening compositions | PROCTER & GAMBLE (US) | 1998-10-07 | — | — | CN | claimed |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | disclosed |
| US-20230241244-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-03 | — | — | US | disclosed |
| US-11433143-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-06 | — | — | US | disclosed |
| EP-4045054-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | The Regents of the University of California (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076630-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200197534-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-25 | — | — | US | disclosed |
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-1986607-A2 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | Neopharm, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-4329289-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4314085-A | Intermediates for preparing adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4304721-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-12-08 | — | — | US | disclosed |
| US-4301300-A | ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-11-17 | — | — | US | disclosed |
| US-4285873-A | ANTIANDROGENS | HOFFMANN-LA ROCHE INC. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4281189-A | Sulfonamide intermediates for adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4278608-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-14 | — | — | US | disclosed |
| US-4247710-A | THE 3'-HYDROXY, -BENZYLOXY, OR -HALO DERIVATIVES OF METHYL 4-((2'-HYDROXYPROPYL)OXY)PHENYLACETATE | HOFFMANN-LA ROCHE INC. (US) | 1981-01-27 | — | — | US | disclosed |
| US-4202978-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE, ANTISECRETORY, SPASMOLYTIC | HOFFMANN-LA ROCHE INC. (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197534-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | IDO1, IDO2, BID | CA1 533/4885SLC1A3 3824/4885SLC1A2 3057/4885 |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | CA1 458/4885SLC1A3 3797/4885SLC1A2 3299/4885 |
| US-11433143-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | CA1 533/4885SLC1A3 3824/4885SLC1A2 3057/4885 |
| US-20230241244-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | IDO1, IDO2, BID | CA1 533/4885SLC1A3 3824/4885SLC1A2 3057/4885 |
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | PHOSPHO1, SGMS1, SGMS2 | CA1 4204/4885SLC1A3 4780/4885SLC1A2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.